Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers.
about
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.Key questions about the checkpoint blockade-are microRNAs an answer?The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumabPretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysis
P2860
Q47102520-A7853B04-21B4-45B6-A67E-26F63502F9B9Q50057781-0D09218D-34F4-447F-8D6A-DC66B889DC55Q55262520-15101A61-9301-4C60-AE06-B7CD7752B953Q55339993-6264FDB6-4405-49A0-B709-E30638D838B4Q55717841-70F65385-A191-4482-BEF8-8ADFD24A05D8Q56888756-CAA4B2E4-FA79-4054-82FA-8A29C3F91D8BQ58700048-869F131F-B8B9-4C05-8429-8C9FEB81D13D
P2860
Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Predicting response and toxici ...... le blood and clinical markers.
@en
type
label
Predicting response and toxici ...... le blood and clinical markers.
@en
prefLabel
Predicting response and toxici ...... le blood and clinical markers.
@en
P2860
P50
P921
P356
P1476
Predicting response and toxici ...... ble blood and clinical markers
@en
P2093
Andrew Rowland
P2860
P2888
P304
P356
10.1038/BJC.2017.274
P407
P50
P5008
P577
2017-08-24T00:00:00Z